SALT LAKE CITY, May 20, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that it will be reporting data on its lead oncology candidate, Azixa™ (MPC-6827), currently in three Phase 2 studies for the treatment of glioblastoma multiforme and metastatic melanoma, during poster presentations at the 2010 Annual American Society of Clinical Oncology (ASCO) Meeting, being held June 4-8, 2010, in Chicago, IL. In addition to these presentations, an abstract on MPC-3100, the Company’s novel, fully-synthetic, orally-bioavailable, small-molecule inhibitor of Heat shock protein 90 (Hsp90), has been accepted by ASCO for publication.
